Find a participating AIRFLOW-3 Clinical Trial site or get the latest news and media updates on Nuvaira.
Locate a Clinic
Find a clinic near you that offers treatment with the dNerva Lung Denervation System as part of the AIRFLOW-3 Clinical Trial.
Treatment Locations in the United States
Treatment Locations in Europe
Contact us to get more information on referring patients to the AIRFLOW-3 Clinical Trial.
News and Media
Jan 25, 2022
300 Patients Treated Worldwide with dNerva® Targeted Lung Denervation therapy MINNEAPOLIS, January 25, 2022 – Nuvaira, a developer of novel therapeutic strategies…
Aug 11, 2021
Nuvaira Announces AIRFLOW-3 COPD Pivotal Trial Milestone 100 Randomized Patients; Inspire’s CEO Tim Herbert appointed Chairman of the Board MINNEAPOLIS, August…
Nov 23, 2020
Nuvaira Announces Published Two-Year Results in COPD Patients treated with Targeted Lung Denervation
AIRFLOW-2 two-year data confirm sustained reduction of severe COPD exacerbation risk vs. a control group. MINNEAPOLIS, Nov. 23, 2020 /PRNewswire/ — Nuvaira, a…
Jun 08, 2020
Inspire Medical Systems CEO Tim Herbert has joined Nuvaira Board of Directors MINNEAPOLIS, June 8, 2020 – Nuvaira, a developer of novel therapeutic strategies…
Feb 04, 2020
Seasoned Veteran Tom Griffin Joins Nuvaira’s Executive Team MINNEAPOLIS, Feb. 4, 2020 – Nuvaira, a developer of novel therapeutic strategies to treat obstructive…
Aug 19, 2019
Nuvaira Announces Peer-Reviewed Publications of Targeted Lung Denervation Mechanisms of Action and Clinical Outcomes
AIRFLOW-2 randomized, sham-controlled one-year data accepted by AJRCCM MINNEAPOLIS, Aug 19, 2019 – Nuvaira, a developer of novel therapeutic strategies to…